Skip to content

Global Support.
One Mission.

Together We Can Find A Cure

Advancing CASK Research since 2020
Australia & USA
Research * Families *Global Collaboration

Donate Now

About the Foundation

Our vision is to advance medical research with the foremost objective being to find a cure for CASK gene mutations and associated conditions related to CASK.

Learn More

We Support the CASK Community

Newly Diagnosed

Information and resources about CASK disorders and find out how to connect with other CASK Parents.

Learn More

Research

ACNRF is committed to establish and help fund research into finding a cure for CASK disorders.

Learn More

Patient Database

ACNRF have partnered with RARE-X to drive a Data Collection Program for CASK and related conditions.

Learn More

Donate

Your support and contributions will enable us to facilitate research improving the quality of life of those diagnosed with CASK Gene Disorders.

Donate Today

Therapies

Early intervention is specialised support for children which aims to promote a child’s development, family and child’s wellbeing and assisting the child to take part in their community.

Learn More

CASK Coalition​

The aim of the CASK Coalition is to harmonize and mobilize the full force of CASK foundations toward advancing treatments and a cure for CASK disorders.

Learn More

Real Stories. Real Strength.

Behind every rare diagnosis is a powerful human story. Meet our heroes living with CASK and share in their journeys of resilience, challenge, and hope and those we honour who are no longer with us.

These are the voices of our community. These are their legacies.

Read Our Stories
Enora
Cure Cask (2)

Cure Cask Annual Dinner 2026​

Tickets are available now for this years Cure Cask Annual Dinner. Get in quick!
Read more
audrey

CURE AUDREY CAMPAIGN

The Audrey Campaign Raises Over $40,000 for CURE CASK
Read more
dinner 2023

Dinner and Dance by the Bay for CASK 2023

$46,100.00 total funds raised!
Read more
dinner 2024

ACNRF Annual Gala Dinner 2024

$64,000.00 total funds raised!
Read more
cure cask

Cure Cask

We’re excited to share that our community is growing and evolving. To make it easier for everyone to support our mission, we’ve brought together our websites under one united name CURE CASK.
Read more

News & Updates

How you can help

Raise Awareness

Fundraise

Become a Sponsor

DONATE AUSTRALIA
DONATE USA
SHOP AUSTRALIA
SHOP USA
FUNDRAISE AUSTRALIA
FUNDRAISE USA

Subscribe to our newsletter

Subscribe to our newsletter for the latest research, events, fundraising campaigns, and what’s happening in our community—delivered straight to your inbox.

Lavvina Thiyagarajan

MBBS

Lavvina is a clinical genetics fellow from NSW, Australia with a background in general paediatrics. She has practiced in multiple tertiary paediatric hospitals in Australia, both in general paediatrics and clinical genetics. She currently provides specialist advice for the NGO, Taking Paediatrics Abroad and is a member of GeneEQUAL, an inclusive research group aiming to improve accessibility of genetic testing and care for people with intellectual disability by co-design.

Lavvina’s clinical interests are in the genetics of autism, intellectual disability and immunogenomics. She is particularly passionate about including the patient groups she works with in research and healthcare decisions.

Lavvina is affiliated with The Children’s Hospital Westmead and the University of New South Wales where she is undertaking a Masters by Research, co-producing a model of genetic healthcare that aligns with the preferences of Autistic people.

Permission to Use Photos and Media

I, the undersigned, give my consent to the Angelina CASK Neurological Research Foundation Ltd and Angelina CASK Neurological Research Foundation Inc (ACNRF) to use photographs, videos, or other media featuring me, my child, or an individual under my legal guardianship (“Media Materials”).

This consent permits ACNRF to use these Media Materials for purposes such as:

  • Raising awareness of CASK-related disorders
  • Promoting ACNRF’s initiatives, campaigns, and programs
  • Sharing on ACNRF’s website, social media, newsletters, and other communication channels
  • Use in advertising, educational resources, and fundraising efforts.

I understand that these materials may be distributed publicly and may appear in print, digital, and other media formats worldwide and in perpetuity.

Terms and Conditions:

1. Usage Rights: I grant ACNRF the right to edit, adapt, or modify the Media Materials as needed for the purposes outlined above.

2. No Compensation: I acknowledge that no monetary or other compensation will be provided for the use of the Media Materials.

3. Release of Claims: I waive any rights to inspect or approve the final product and release ACNRF from any claims, liabilities, or damages related to the use of the Media Materials, including but not limited to claims of defamation, privacy, or copyright infringement.

4. Ownership Confirmation: I confirm that I have the authority to grant these rights for the provided Media Materials and that they do not infringe on the rights of any third party.

This authorisation is voluntary and may be revoked by written notice to ACNRF at any time, though I understand that materials already published may not be withdrawn.

“In some ways, that CASK-linked pathology is degenerative in nature provides a positive outlook. Because microcephaly in CASK-linked pathology progresses postnatally, there may be a temporal window when therapeutic intervention might prevent or slow further brain cell loss. Regression, even in adolescence, has also been observed in some cases of MICPCH [119], again offering the tantalizing possibility that a therapeutic approach might prevent such decline under conditions when degeneration is known to progress. The potential benefits of intervention might extend even further given that non-cell-autonomous toxicity could also affect functioning of the remaining neurons; reduction of such toxicity, especially when coupled with high-intensity rehabilitative measures [120], might offer real hope for a positive impact on functional outcomes.”   

https://www.mdpi.com/2073-4409/11/7/1131/htm